Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer
Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, ... Read More
Aravive Biologics’ AVB-S6-500 receives FDA fast track designation for ovarian cancer
Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel drug AVB-S6-500, aimed at ... Read More